logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
钟

钟润波｜Runbo Zhong

shanghai chest hospital邮箱:louyq@hotmail.com
H指数:22
被引数:1,618
浏览量:0

个人简介

任职于附属胸科医院，硕士生导师，学科为内科学（呼吸系病）。主持科研项目包括：上海市2020年度“科技创新行动计划”医学创新研究专项“免疫检查点抑制剂联合安罗替尼二线治疗难治型广泛期小细胞肺癌的临床研究”（2020-12至2023-11，30万元）；上海市自然科学基金“新LncRNA FAM207BP调控STAT3-SOX5信号轴介导肺腺癌对PD-1单抗耐药的功能和机制研究”（2019-07至2022-06，20万元）；国家青年自然科学基金“唑来膦酸联合树突状细胞、γδT细胞免疫治疗肺癌的机制研究”（2013-01至2015-12，23万元）。

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR -mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study

一线口服长春瑞滨联合伏沃替尼在耐药EGFR突变非小细胞肺癌中的疗效与安全性：一项多中心、非随机、两队列研究的方案

Therapeutic Advances in Medical Oncology
IF4.2
2026-06-110
PRE
Bo Zhang; Yanwei Zhang; Chunlei Shi; Zhiqiang Gao; Runbo Zhong; Rong Qiao; Shuang Li; Hua Zhong; Baohui Han
Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis

度鲁特韦联合安罗替尼与度鲁特韦单药作为广泛期小细胞肺癌的维持治疗（DURABLE）：一项多中心、随机、II期试验及生物标志物分析

Nature Communications
IF15.7
2026-05-250
OAAI
Bo Zhang; Runbo Zhong; Chunlei Shi; Tianqing Chu; Wei Zhang; Huimin Wang; Xin Gan; Zhihong Zhang; Changbin Zhu; Xing Li; Wenzhong Su; Juan Li; Yanwei Zhang; Baohui Han; Hua Zhong
PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non–small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors

PD-L1表达与罕见EGFR突变型晚期非小细胞肺癌经一线二代EGFR酪氨酸激酶抑制剂治疗后的不良预后相关，且与EGFR亚型无关

Cancer
IF5.1
2026-05-150
PRE
Hongping Jin MS; Yue Wang MS; Yidan Zhang MS; Yiqing Wu MS; Tengfei Liu MD; Jianlin Xu MD; Tianqing Chu MD, PhD; Hua Zhong MD, PhD; Huizhen Yang MD, PhD; Runbo Zhong MD, PhD
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer

MEK/RTK通路的协同抑制在KRAS突变型非小细胞肺癌中具有高疗效

Signal Transduction and Targeted Therapy
IF52.7
2025-09-120
OAAI
Jun Lu; Minjuan Hu; Yikai Zhao; Tianqing Chu; Wei Zhang; Yijia Zhou; Xinlei Cai; Jun Wu; Liang Hu; Chunlei Shi; Liwen Xiong; Aiqin Gu; Huimin Wang; Yanwei Zhang; Yuqing Lou; Runbo Zhong; Zhiqiang Gao; Hongyu Liu; Chao Zhou; Yingli Wu; Liang Zhu; Hua Zhong; Hongbin Ji; Baohui Han
A phase II trial of autologous cytokine-induced killer (CIK) therapy plus toripalimab with or without chemotherapy as first-line treatment in advance NSCLC

一项关于自体细胞因子诱导的杀伤细胞（CIK）疗法联合托瑞帕利单抗，并根据情况联合或不联合化疗作为晚期非小细胞肺癌（NSCLC）一线治疗的II期临床试验。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Han, B.; Zhong, H.; Zhong, R.; Qiao, R.; Xu, J.; Zhang, W.; Shi, C.; Xiong, L.; Chen, S.; Zhang, M.
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy
CLINICAL AND TRANSLATIONAL MEDICINE
IF6.8
2023-05-301
OAAI
Chu, Tianqing; Yuan, Jie; Lu, Jun; Nie, Wei; Zhong, Runbo; Zhang, Bo; Zhang, Wei; Shi, Chunlei; Qian, Jialin; Zhang, Yanwei; Zhang, Xueyan; Teng, Jiajun; Gao, Zhiqiang; Lou, Yuqing; Li, Jiaqi; Qiang, Huiping; Zhang, Chao; Li, Jin; Xia, Xuefeng; Zhong, Hua; Han, Baohui

研究方向

肺部肿瘤的多学科治疗
韩
韩宝惠
H 指数:56论文数:711被引数:1.4万
J
Jianlin Xu
H 指数:26论文数:143被引数:2,393
钟
钟华
H 指数:22论文数:109被引数:1,830
T
Tianqing Chu
H 指数:22论文数:111被引数:1,593
J
Jun Lü
H 指数:34论文数:243被引数:3,979
Y
Yuqing Lou
H 指数:33论文数:380被引数:5,016
T
Tianqing Chu
H 指数:14论文数:77被引数:946
Y
Yanwei Zhang
H 指数:26论文数:192被引数:2,905
Y
Yinchen Shen
H 指数:19论文数:100被引数:986
H
Hua Zhong
H 指数:26论文数:115被引数:6,073